Summary
To determine the role of growth hormone in overnight insulin requirements and lipolysis, five patients with chronic growth hormone deficiency and Type 1 (insulin-dependent) diabetes mellitus and six control patients with diabetes were each studied on two separate nights. Insulin was infused at a variable rate throughout one night to maintain euglycaemia and fixed at 04.00 hours on another. During the variable infusion, euglycaemia was maintained in control patients by a 36% increase in insulin infusion rate between 03.00 and 08.00 hours while a 46% decrease in the rate was required in growth hormone deficient patients (p<0.02). Despite this difference, mean free insulin values were equivalent. This finding is suggestive of increased insulin clearance in growth hormone sufficient patients. Glucose levels rose in control and fell in growth hormone deficient patients when insulin infusion rates were fixed at 04.00 hours. Glycerol production and non-esterified fatty acid concentrations were significantly lower in the growth hormone deficient diabetic patients, p<0.001, and when normalized with a heparin infusion, had no effect on insulin requirements. We conclude that: (1) growth hormone contributes to the development of the “dawn phenomenon,” possibly by increasing insulin clearance (2) growth hormone helps sustain nocturnal lipolysis in Type 1 diabetes and (3) non-esterified fatty acids are not involved in the dawn phenomenon.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Clarke WL, Haymond MW, Santiago JV (1980) Overnight basal insulin requirements in fasting insulin dependent diabetic patients. Diabetes 29: 78–80
Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A (1981) The dawn phenomenon, early morning glucose rise: implications for diabetic intraday blood glucose variation. Diab Care 4: 579–585
Bright GM, Melton TW, Rogol AD, Clarke WL (1980) Failure of cortisol blockade to inhibit early morning increase in basal insulin requirements in fasting Type 1 (insulin-dependent) diabetes. Diabetes 29: 662–664
Skor DA, White NH, Thomas L, Shah SD, Cryer PE, Santiago JV (1983) Examination of the role of the pituitary-adrenal axis, counterregulatory hormones, and insulin clearance in variable nocturnal insulin requirements in insulin-dependent diabetes. Diabetes 32: 403–407
Campbell PJ, Bolli GB, Cryer PE, Gerich JE (1985) Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. N Engl J Med 312: 1473–1479
Skor DA, White NH, Thomas L, Santiago JV (1985) Influence of growth hormone on overnight insulin requirements in insulindependent diabetes. Diabetes 34: 135–139
Mauras N, Rogol AD, Clarke WL (1986) Failure to detect the “dawn phenomenon” in non diabetic subjects with markedly different patterns of nocturnal growth hormone secretion. J Clin Endocrinol Metab 62: 975–979
Macgorman LR, Consoli A, Jensen MD, Miles JM (1987) Importance of growth hormone in the maintenance of basal lipolysis in normal man. Diabetes 36 [Suppl 1]: 317
Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA (1983) Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72: 1737–1747
Lee KU, Lee HK, Koh CS, Min HK (1988) Artificial induction of intravascular lipolysis by lipid-heparin infusion leads to insulin resistance in man. Diabetologia 31: 285–290
Hosaka K, Kikuchi T, Mitsuhida N, Kawaguchi A (1981) A new colorimetric method for the determination of NEFAs with acyl-CoA synthetase and acyl-CoA oxidase. J Biochem 89: 1799–1803
Meng HC, Edgren B (1963) Source of plasma NEFAs in dogs receiving fat emulsion and heparin. Am J Physiol 204: 691–695
Nakagawa S, Nakayama H, Sasaki T et al. (1973) A simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes 22: 590–600
Kuzuya H, Blix PM, Horwitz DL, Steiner DN, Rubenstein AH (1977) Determination of free and total insulin and C-peptide in insulin-treated diabetic patients. Diabetes 26: 22–29
Ensinck JW (1983) Immunoassays for glucagon. In: Lefebvre P (ed) Glucagon handbook of experimental pharmacology, Vol 66. Springer-Verlag, New York, pp 203–221
Schalch DS, Parker ML (1964) A sensitive double antibody immunoassay for human growth hormone in plasma. Nature 203: 1141–1142
Farmer RW, Pierce CE (1974) Plasma cortisol determination: radioimmunoassay and competitive protein binding compared. Clin Chem 20: 411–414
Shah SD, Clutter WE, Cryer PE (1985) External and internal standards in the single isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. J Lab Clin Med 106: 624–629
Pinter JK, Hayashi JA, Watson JA (1967) Enzymic assay of glycerol, dihydroxy-acetone, and glyceraldehyde. Arch Biochem Biophys 121: 404–414
Lowry OH, Passonneau JV, Hasselberger FX, Schulz DW (1964) Effect of ischemia on known substrates and cofactors of the glycolytic pathway in brain. J Biol Chem 239: 18–30
Cahill GF Jr, Herrera MG, Morgan AP et al. (1966) Hormonefuel interrelationships during fasting. J Clin Invest 45: 1751–1769
Clutter WE, Bier DM, Shah SD, Cryer PE (1980) Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest 66: 94–101
Beylot M, Martin C, Beaufrere B, Riou JP, Mornex R (1987) Determination of steady-state and nonsteady-state glycerol kinetics in humans using deuterium-labeled tracer. J Lipid Res 28: 414–422
Bolli GB (1988) The dawn phenomenon: its origin and contibution to early morning hyperglycaemia in diabetes mellitus. Diabetes & Metabolisme (Paris) 14: 675–686
Utter M, Scrutton M (1969) Pyruvate carboxylase. Curr Topics Cell Regul 1: 253–296
Skor DA, White NH, Thomas L, Santiago JV (1984) Relative roles of insulin clearance and insulin sensitivity in the pre-breakfast increase in insulin requirements in insulin-dependent diabetic patients. Diabetes 33: 60–63
Dux S, White NH, Skor DA, Santiago JV (1985) Insulin clearance contributes to the variability of nocturnal insulin requirement in insulin-dependent diabetes mellitus. Diabetes 34: 1260–1265
Brennan JR, Gebhart SP, Blackard WG (1985) Pump-induced insulin aggregation: a problem with the Biostator. Diabetes 34: 353–359
Periello G, De Feo P, Bolli G (1988) The dawn phenomenon: nocturnal blood glucose homeostasis in Type 1 (insulin dependent) diabetes mellitus. Diab Med 5: 13–21
Arslanian SA, Ohki Y (1988) Pathogenesis of the dawn phenomenon in adolescents with Type 1 (insulin dependent) diabetes mellitus. Clin Res 36: 809 A
De Feo P, Perriello G, Ventura MM et al. (1986) Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: relevance to the pathogenesis of the dawn phenomenon. Diabetologia 29: 475–480
Perriello G, De Feo P, Torlone E et al. (1990) Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33: 52–59
Campbell PJ, Gerich JE, Cryer PE (1986) Occurrence of dawn phenomenon without change in insulin clearance in patients with insulin-dependent diabetes mellitus. Diabetes 35: 749–752
Nurjihan N, Campbell PJ, Kennedy FP, Miles JM, Gerich JE (1986) Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans. Diabetes 35: 1326–1331
Randle PJ, Hales CN, Garland PB, Newsholme EA (1963) The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet I: 785–789
Koivisto VA, Yki-Jarvinen H, Helve E, Karonen SL, Pelkonen R (1986) Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 35: 78–82
Perriello G, De Feo P, Torlone E et al. (1991) The dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 34: 21–28
Rizza RA, Mandarino LJ, Gerich JE (1982) Effects of growth hormone on insulin action in man mechanisms of insulin resistance, impaired suppression of glucose production and impaired stimulation of glucose utilization. Diabetes 31: 663–669
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boyle, P.J., Avogaro, A., Smith, I. et al. Absence of the dawn phenomenon and abnormal lipolysis in Type 1 (insulin-dependent) diabetic patients with chronic growth hormone deficiency. Diabetologia 35, 372–379 (1992). https://doi.org/10.1007/BF00401205
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00401205